Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma is set to transfer the rights to distribute the anti-allergic drug Intal (sodium cromoglycate) to Sanofi-aventis effective on 1 January 2011.
Subscribe to our email newsletter
Astellas Pharma is also expected to transfer the manufacturing and marketing approval for all Intal products to Sanofi-aventis as of 1 October 2010.
Intal is a chemical mediator release inhibitor discovered by the British company Fisons (currently Sanofi-aventis Group) and has seven different formulations.
Intal is indicated for a wide range of allergic diseases, such as allergic conjunctivitis/vernal conjunctivitis, allergic rhinitis, atopic dermatitis caused by food allergies and bronchial asthma.